ATP5MF

Across TCGA pan-cancer cohorts, ATP5MF mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ATP5MF data layer compared with 24 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ATP5MF mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP5MF expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

LSCC, CCRCC, and PDAC are the cancer types where ATP5MF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.882	0.993	.004	17	view →
CCRCC	OS	Median	III,IV	0.877	0.515	.006	13	view →
PDAC	DFS	Tertile	III,IV	0.295	0.735	.024	6	view →
HNSC	OS	Tertile	III,IV	0.812	0.968	.009	3	view →
GBM	OS	Median	All	0.526	0.274	.035	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ATP5MF–LSCC (DFS)

Open the LSCC breakdown →